Table 1.

Gene expression variability upon Abi1 depletion in primary PyMT breast cancer tumors defined by RNA‐seq.

Mouse ID		G144	G164	G184	G174	Fold change depletion
Genotype		fl/wt	fl/wt	fl/fl	fl/fl
Cre		‐	+	‐	+	Heterozygous	Homozygous	Ratio	Treatment Effect a
Gene expression (RNA‐seq from primary tumors)	Abi1	14389	7343	15682	1018	1.96	15.40	7.86	Yes
	Abi2	8173	7189	8031	9719	1.14	0.83	0.73	No
	Abi3	146	271	343	195	0.54	1.76	3.26	Yes
	Nckap1	36435	34964	40591	38802	1.04	1.05	1.00	No
	Wasf1	88	66	85	118	1.33	0.72	0.54	No
	Wasf2	8563	10349	13894	11087	0.83	1.25	1.51	No
	Wasf3	261	151	95	221	1.73	0.43	0.25	Yes
	Brk1	10240	9103	11091	9920	1.12	1.12	0.99	No
	Cyfip1	23448	22528	31708	23030	1.04	1.38	1.32	No
	Cyfip2	521	1289	1633	580	0.40	2.82	6.97	Yes
	Rac1	25732	22621	27209	24431	1.14	1.11	0.98	No
	Ndel1	10923	10842	15082	13030	1.01	1.16	1.15	No

^aTreatment effect is ‘positive’ (yes) if the fold change of gene expression for heterozygous and homozygous mice changed more than 1.5 times (bold text) in any direction and ‘negative’ (no) in other cases. RNA‐seq. expression profiles of WAVE complex, and Rac1 and Ndel1 genes (involved in WAVE complex stability and functionality) show the differences between heterozygous vs. homozygous Abi1 KO PyMT mammary tumors.